Citations

Clear

4847 citation(s) found for "Tu, Eric".

Anatomic and Radiographic Patterns of Radiation Failure in Recurrent Clival Chordomas
Dang, Danielle , Brown, Paul D., Pollock, Bruce E. , Link, Michael J., Celda, María Peris, Mahajan, A., Gompel, Jamie J. Van, Laack, N., Hong, Sukwoo , Gompel, Jamie J. Van , Lehrer, Eric J.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 27, 2026 | Volume: 87 | Issue: No issue available | Pages: No page available

10.1055/s-0046-1818844 Get It

Metabolomic Profiling of Meningiomas Reveals Tumor-Specific Features but does not Distinguish Meningioma Subtypes
Syed, Hashim S., Xu, Linjing, Dougherty, Mark C. , Taylor, Eric B. , Hansen, Marlan R.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 27, 2026 | Volume: 87 | Issue: No issue available | Pages: No page available

10.1055/s-0046-1818748 Get It

Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation
SKLEPINSKI, STACEY , Ratzki-Leewing, Alexandria A , Swarna, Kavya, Deng, Yihong, Neumiller, Joshua J, Galindo, Rodolfo J, Umpierrez, Guillermo E, Ross, Joseph S., Borah, B., Maron, Bradley A. , Mickelson, Mindy M, McCoy, Rozalina Grubina, Umpierrez, Guillermo E. , Sklepinski, Stacey , Ratzki-Leewing, Alexandria A , Umpierrez, Guillermo E. , Montori, Victor M , McCoy, Rozalina Grubina , Herrin, Jeph , Deng, Yihong , Polley, Eric C. , Neumiller, Joshua J. , Galindo, Rodolfo J. , Ross, Joseph S. , Brito, Juan P. , Montori, Víctor M. , Borah, Bijan J, Mickelson, Mindy M , McCoy, Rozalina G.

Mayo Clinic

BMJ Open Diabetes Research & Care | February 27, 2026 | Volume: 14 | Issue: 1 | Pages: e005646

10.1136/bmjdrc-2025-005646 | PMID 41760122 Get It

Introduction To examine within-class sulfonylurea safety, we compared risks of major adverse cardiovascular events (MACE) and severe hypoglycemia among adults with type 2 diabetes (T2D) and moderate cardiovascular risk following sulfonylurea initiation. Research design and methods We conducted a target trial emulation including adults ≥21 years old with T2D and moderate cardiovascular risk who initiated glimepiride, glipizide or glyburide between 2014 and 2021, using claims data from Optum Labs Data Warehouse and the Medicare fee-for-service 100% sample. Study outcomes were MACE (primary), expanded MACE and its components and emergency department or hospital encounters for hypoglycemia, ascertained during follow-up through 2022. Inverse probability of treatment weighting (IPTW) was applied using propensity scores estimated using the super learner ensemble, and outcomes were examined using IPTW Cox proportional hazards models. Results The weighted study cohort comprised 314 699 patients (mean age 66.9 years, 52.0% men, 76.6% non-Hispanic white). At 1 year, MACE was experienced by 2.5%, 2.7% and 2.8% of patients starting glimepiride, glipizide and glyburide, respectively. Compared with glimepiride, glyburide and glipizide were associated with higher risk of MACE (HR 1.10, 95% CI 1.05 to 1.16 for glyburide; HR 1.05, 95% CI 1.03 to 1.07 for glipizide). At 1 year, severe hypoglycemia was experienced by 0.3%, 0.3% and 0.4% of patients starting glimepiride, glipizide and glyburide, respectively. Glyburide was associated with a greater risk of severe hypoglycemia compared with glipizide (HR 1.43, 95% CI 1.23 to 1.65), while glipizide was associated with a lower risk compared with glimepiride (HR 0.82, 95% CI 0.77 to 0.87). Conclusions Among adults with T2D and moderate cardiovascular risk, glimepiride was associated with lowest risk of MACE and glipizide with lowest risk of severe hypoglycemia. These results can help inform treatment selection if sulfonylureas are used for glucose-lowering.
Inflammation, Limbic White Matter Microstructure, and Clinical Symptoms in Retired American Football Players With Repetitive Head Impacts
Emanuel, Olivia M. , Miner, Annalise E., Lee, Shannon, Tanner, Jared J. , Holgerson, Allison A. , Tuz‐Zahra, Fatima , Tripodis, Yorghos, Adler, Charles H., Balcer, Laura J. , Bernick, Charles, Zetterberg, Henrik, Blennow, Kaj, Ashton, Nicholas J., Peskind, Elaine R. , Banks, Sarah J., Barr, W, Wethe, Jennifer V. , Cantu, Robert C., Coleman, Michael J., Dodick, David W., McClean, M M, Mez, Jesse, Palmisano, Joseph, Martin, Brett, Lin, Alexander P., Pasternak, Ofer , Cummings, Jeffrey L., Reiman, Eric M., Shenton, Martha E., Stern, Robert A., Bouix, Sylvain, Alosco, Michael L., Tripodis, Yorghos , Lee, Shannon Y. , Lee, Shannon Y , Matusz, Emily F , Tuz-Zahra, Fatima , Tripodis, Yorghos , Adler, C H , Balcer, Laura J , Bernick, Charles , Zetterberg, Henrik , Blennow, Kaj , Ashton, Nicholas J , Peskind, Elaine R , Banks, Sarah J , Barr, William B , Wethe, Jennifer V , Cantu, Robert C , Coleman, Michael J , Dodick, David W , McClean, Michael D , Mez, Jesse , Palmisano, Joseph , Martin, Brett , Lin, Alexander P , Pasternak, Ofer , Koerte, Inga K , Cummings, Jeffrey L , Reiman, Eric M , Shenton, Martha E , Stern, Robert A , Bouix, Sylvain , Alosco, Michael L , Asken, Breton M , Miner, Annalise E., Marsiske, Michael , Ly, Monica T. , Adler, Charles H. , Bernick, Charles , Blennow, Kaj , Ashton, Nicholas J. , Banks, Sarah J. , Barr, William , Cantu, Robert C. , Coleman, Michael J. , Dodick, David W. , Mez, Jesse , Palmisano, Joseph , Reiman, Eric M. , Shenton, Martha E. , Alosco, Michael L. , Asken, Breton M.

Mayo Clinic

Neurology | February 25, 2026 | Volume: 106 | Issue: 6 | Pages: No page available

10.1212/wnl.0000000000214646 | PMID 41740080 Get It

Factors associated with subjective cognitive complaints in former American football players
Adler, Jennifer S. , Yhang, Eukyung , Tripodis, Yorghos, Adler, Charles H., Balcer, Laura J. , Bernick, Charles, Ashton, Nicholas, Zetterberg, Henrik, Blennow, Kaj, Peskind, Elaine, Banks, Sarah J., Barr, W, Wethe, Jennifer V. , Bondi, Mark W., Delano-Wood, Lisa, Cantu, Robert C., Coleman, Michael J., Dodick, David W., Daneshvar, Daniel H., McClean, M M, Mez, Jesse, Palmisano, Joseph N., Martin, Brett, Lin, Alexander P., Bouix, Sylvain, Cummings, Jeffrey L., Shenton, Martha E., Reiman, Eric M., Stern, Robert A., Alosco, Michael L. , Alosco, Michael L , Wethe, Jennifer V , Ly, Monica T. , Tripodis, Yorghos , Adler, Charles H. , Bernick, Charles , Blennow, Kaj , Peskind, Elaine R. , Banks, Sarah J. , Barr, William , Bondi, Mark W. , Delano‐Wood, Lisa , Cantu, Robert C. , Coleman, Michael J. , Dodick, David W. , Daneshvar, Daniel H. , McClean, Michael D , Mez, Jesse , Palmisano, Joseph , Koerte, Inga K , Bouix, Sylvain , Cummings, Jeffrey L. , Shenton, Martha E. , Reiman, Eric M.

Mayo Clinic

Journal of the International Neuropsychological Society | February 25, 2026 | Volume: 32 | Issue: 2 | Pages: 132-146

10.1017/s1355617726101866 | PMID 41738687 Get It

Abstract Objective: Subjective cognitive complaints (SCC) can precede cognitive decline and are associated with demographic, exposure, lifestyle, and psychological factors. Prevalences of SCC and their correlates in individuals with repetitive head impacts (RHI) are poorly understood. This study characterized SCC in former elite American football players by frequency, mood and behavioral correlates, concordance with informant reports, and associations with neuropsychological test performance, cerebrospinal fluid (CSF), and magnetic resonance imaging (MRI) markers of neurodegeneration. Method: Former American football players ( n = 180) completed measures of global and domain-specific SCC, neuropsychiatric symptom questionnaires, neuropsychological testing, lumbar puncture, and MRI. Elastic net regression evaluated the relative importance of potential SCC correlates. Intraclass correlation coefficients measured concordance between self and informant reports. Multiple linear regressions tested associations between SCC and verbal memory and executive functioning scores. CSF Aβ 1-42 , p-tau 181 , t-tau, neurofilament light (NfL), hippocampal volume, and regional cortical thickness were examined for their potential associations with SCC. Results: Rates of SCC ranged from 43 to 77% depending on the domain. Symptoms of depression, impulsivity, and anxiety were strongly associated with SCC. Self- and informant-reported SCC showed moderate inter-rater agreement. Adjusting for age, race, education, APOE ϵ4 carrier status, and depressive symptoms, SCC were associated with lower objective verbal memory and executive functioning performance. SCC were associated with lower parahippocampal cortical thickness but not with hippocampal volume or any of the measured CSF tests. Conclusions: SCC are strongly associated with neuropsychiatric factors in former American football players. SCC may also be a marker of cognitive decline and neurodegeneration.
Urine Drug Testing: Service Models and Laboratory Practices to Meet Clinical Care Needs
Stefan, Cristiana , Zhou, Janet R. , Franssen, Eric J. F. , Langman, Loralie J., Fu, Lei , Fu, Lei , Jung, Benjamin

Mayo Clinic

Therapeutic Drug Monitoring | February 23, 2026 | Volume: 48 | Issue: 2 | Pages: 185-195

10.1097/ftd.0000000000001428 | PMID 41729621 Get It

Abstract: Urine drug testing (UDT) is an important laboratory tool utilized in various healthcare settings to identify drug or toxic exposures. It has wide clinical applications, including but not limited to detecting substance misuse, monitoring treatment effectiveness and compliance, and identifying substances in affected patients. Depending on the clinical care setting and patient population, the UDT service model and practice are important decisions by the clinical laboratory to meet the needs of the healthcare providers. In addition, clinical laboratories must appreciate the testing process and unique aspects of this toxicology test, from specimen collection and integrity, testing methods, to the result reporting and interpretation. Each phase has specific quality requirements to ensure the accuracy and appropriate interpretation of results. This review aims to summarize the preanalytical, analytical, and postanalytical considerations of clinical laboratories when implementing the test or providing support to clinicians in point-of-care settings. To bring awareness of the limitations inherent to different analytical methodologies, this review discusses important considerations and presents the current gaps, opportunities, and recommendations for quality improvement and standardization. This article may serve as a framework for clinical laboratory directors and other laboratory professionals to review their current provision of UDT and provide recommendations on various important aspects when considering changes to the test service models to meet their local clinical needs, including when introducing new test methods. It may also help physicians and healthcare providers appreciate the complexities of UDT and recognize the challenges in clinical interpretation.
Variation in Lipid Management for Atherosclerotic Cardiovascular Disease Across US Health Systems
Shah, Nishant , Peterson, Eric D. , Shrader, Peter, Shoji, Satoshi , Freeman, Nikki , Martin, Seth S., Allred, Clint, Fernandez, S. A., Chamberlain, Alanna M., Arnold, Jonathan , Shapiro, Michael D., Priest, Elisa L. , Syed, Mahanaz, Kirchner, H. Lester , Leja, Monika, Kalich, Bethany , Jin, Ran , Navar, Ann Marie, Peterson, Eric D. , Chamberlain, Alanna M. , Arnold, Jonathan , Shah, Nishant P , Martin, Seth S , Fernandez, Soledad , Chamberlain, Alanna M , Shapiro, Michael D , Effron, Mark B , Syed, Mahanaz , Kirchner, H Lester , Kalich, Bethany , Jin, Ran , Wojcik, Cezary , Navar, Ann Marie , Shrader, Peter, Martin, Seth S. , Ahmad, Zahid , Jones, Laney K , Návar, Ann Marie

Mayo Clinic

Circulation: Population Health and Outcomes | February 20, 2026 | Volume: 19 | Issue: 4 | Pages: No page available

10.1161/circoutcomes.125.012622 | PMID 41717695 Get It

BACKGROUND: While health systems have implemented resources to improve lipid management in people with atherosclerotic cardiovascular disease, the population-level effectiveness is unclear. METHODS: Electronic health record data from patients with atherosclerotic cardiovascular disease between January 1, 2021, and December 31, 2023, across 16 US academic health systems were analyzed. Atherosclerotic cardiovascular disease (defined by diagnosis and procedure codes) was established on or before the index date defined as the date of the most recent LDL-C (low-density lipoprotein-cholesterol) or the last day of the study period for those without an LDL-C available. Systems were surveyed to identify lipid management programs (eg, prevention/lipid clinic, electronic health record–based tools, and lipid management algorithms). Sequential multilevel multivariable logistic regression modeling was used to (1) assess the system-level association between an LDL-C <70 mg/dL and the presence of lipid management programs, adjusting for patient-level demographic and clinical characteristics, and (2) whether system-level uptake of statin or nonstatin lipid-lowering therapy was associated with an LDL-C <70 mg/dL. RESULTS: We included 1 738 042 patients with atherosclerotic cardiovascular disease (median, 88 365 per system; range, 17 086–2 48 371). About 81% of the health systems had prevention or lipid clinics. The proportion of those on statins ranged from 31.0% to 60.4% across health systems (median, 46.3%). Lower proportions were observed in the use of high-intensity statins (16.2%–33.1%), nonstatins (2.6%–8.1%), and combination lipid-lowering therapy (1.7%–6.3%). Among those with an LDL-C level available (n=890 521), 42.5% had an LDL-C <70 mg/dL, ranging 35.8% to 49.4% across systems. There was no association between the odds of achieving LDL-C <70 mg/dL and health system lipid management algorithm, prevention clinics/lipid clinics, or electronic health record–based tools. Neither system-level high-intensity statin utilization nor nonstatin use was associated with an LDL-C <70 mg/dL. CONCLUSIONS: Despite variability in lipid management resources and lipid-lowering therapy use across systems, many did not reach an LDL-C <70 mg/dL, and there was low uptake of lipid-lowering therapy. Innovative implementation strategies are needed for system-level lipid management.
Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Locoregional Gastric Adenocarcinoma
Adenocarcinoma, Expert Panel Adjuvant Therapy for Treatment of Locoregional Gastric, Tchelebi, Leila T. , Jin, Zhaohui, Attallah, Joseph, Abood, G., Akselrod, Dmitriy, Codipilly, D. Chamil, Dozois, Eric J. , Hallemeier, Christopher L., Krishan, Jethwa, Kennedy, Timothy, Lee, Percy P., Ling, Diane, Newman, Neil B. , Sharma, Navesh K, Small, William, Russo, Suzanne , Tchelebi, Leila , Jin, Zhaohui , Abood, Gerard, Akselrod, Dmitriy , Anker, Christopher J. , Codipilly, Don C. , Hallemeier, Christopher Leigh , Lee, Percy , Miller, Eric D. , Sharma, Navesh, Small, William , Russo, Suzanne

Mayo Clinic

American Journal of Clinical Oncology | February 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/coc.0000000000001309 | PMID 41712927 Get It

Objectives: To summarize recent high-quality trials and provide an update to the original 2022 American College of Radiology Appropriate Use Criteria for Treatment of Locoregional Gastric Adenocarcinoma. This multi-specialty-led committee included gastrointestinal radiation and medical oncology, gastroenterology, radiology, and surgical oncology. Methods: Using the population, intervention, comparator, outcome, timing, and study design framework, the evidence was assessed using Cochrane and PRISMA 2020 methodology. Eligible studies included prospective Phase II/II trials and select retrospective studies published between 5/1/2020 and 8/1/2025 in the Embase, Medline, and Pubmed databases. Study type and quality were assessed. Well-established RAND-UCLA consensus methodology (modified Delphi) was used to rate the appropriateness of the treatment options. Results: ARS AUC recommendations include adjuvant FLOT chemotherapy for localized gastric adenocarcinoma after neoadjuvant FLOT and surgery, poCT or perioperative chemoimmunotherapy for localized gastric adenocarcinoma, adjuvant chemotherapy +/− CRT for localized gastric adenocarcinoma that undergoes upfront surgery, and systemic therapy alone for localized gastric adenocarcinoma in a medically inoperable patient. Conclusions: This updated ARS AUC summary provides guidelines for the multimodality treatment of resectable gastric adenocarcinoma.
Continuous At-Home Monitoring of Nighttime Bed Behavior in Frontotemporal Dementia
Paolillo, Emily W., Wise, Amy, Kaye, Jeffrey A., Beattie, Zachary , Dhanam, Sreya, Casaletto, Kaitlin B. , Saloner, Rowan, Mendez, Mario F., Vandevrede, Lawren, Ljubenkov, Peter A. , Seeley, William W., Gorno-Tempini, Maria Luisa, Miller, Bruce L., Heuer, Hilary W. , Forsberg, Leah K., Kornak, John , Boeve, Bradley F., Boxer, Adam L., Rosen, Howard J., Walsh, Christine M., Staffaroni, Adam M., Abdullah, Muhammad, Apostolova, Liana , Ece, Bayram, Botha, Hugo, Brushaber, Danielle , Clark, David, Considine, Ciaran , Darby, R. Ryan , Day, Gregory S., Dickerson, Bradford, Dickson, Dennis, Domoto-Reilly, Kimiko, Dwosh, Emily , Faber, Kelley , Fagan, Anne M. , Fields, Julie A. , Fong, Jamie C., Foroud, Tatiana M., Galasko, Douglas R., Gavrilova, Ralitza, Gendron, Tania, Geschwind, Daniel, Ghoshal, Nupur , Goldman, Jill, Graff-Radford, Jonathan, Graff-Radford, Neill, Grant, Ian M., Grossman, Murray, Hales, Chadwick M., Hall, Matthew, Honig, Lawrence S., Hsiung, Ging-Yuek (Robin), Huang, Eric S., Huey, Edward D, Irwin, David, Johnson, Noah, Jones, David T., Kantarci, Kejal, Knopman, David, Kolander, Tyler, Kwan, Justin Y., Lago, Argentina Lario , Lapid, Maria, Lavigne, Shannon B., Lee, Suzee, Litvan, Irene, Lucente, Diane , Mackenzie, Ian R., Masdeu, Joseph C. , Massimo, Lauren , McGinnis, Scott, McMillan, Corey T., Mester, Carly, Miyagawa, Toji , Molden, Joie, Onyike, Chiadi, Pascual, Belen, Paulson, Henry, Petrucelli, Leonard, Pressman, Peter, Rademakers, Rosa, Ramanan, Vijay, Ramos, Eliana Marisa , Rankin, Katherine P., Rao, Meghana, Rascovsky, Katya, Rhoads, Kristoffer , Ritter, Aaron, Rogalski, Emily, Rojas, Julio C., Savica, Rodolfo, Snyder, Allison, Sullivan, Anna Campbell, Syrjanen, Jeremy, Tartaglia, M. Carmela, Taylor, Jack, Weintraub, Sandra, Wint, Dylan , Wong, Bonnie, Yokoyama, Jennifer, Mendez, Mario F. , VandeVrede, Lawren , Paolillo, Emily W. , Wise, Amy B. , Saloner, Rowan , Forsberg, Leah Kathleen, VandeVrede, Lawren , Mendez, Mario , Paolillo, Emily W , Kaye, Jeffrey , Au-Yeung, Wan-Tai Michael , Dhanam, Sreya , Seeley, William W. , Gorno‐Tempini, Maria Luisa , Forsberg, Leah K. , Kremers, Walter K. , Boeve, Bradley F. , Boxer, Adam L. , Rosen, Howard J. , Walsh, Christine M. , Staffaroni, Adam M. , Appleby, Brian S. , Barmada, Sami , Bozoki, Andrea C , Domoto‐Reilly, Kimiko , Galasko, Douglas , Gavrilova, Ralitza H. , Gendron, Tania F. , Geschwind, Daniel H., Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Grossman, Murray, Hales, Chadwick M. , Hall, Matthew , Honig, Lawrence, Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Knopman, David, Kwan, Justin , Lavigne, Shannon B., Léger, Gabriel C. , Litvan, Irene , Mackenzie, Ian R. , Masdeu, Joseph C , McMillan, Corey T. , Mester, Carly , Molden, Joie, Pantelyat, Alexander , Pascual, Belén , Petrucelli, Leonard , Pressman, Peter , Rademakers, Rosa, Rankin, Katherine P. , Rao, Meghana , Rascovsky, Katya, Roberson, Erik D. , Rogalskı, Emily , Rojas, Julio C. , Savica, Rodolfo , Snyder, Allison , Syrjanen, Jeremy A. , Tartaglia, Maria Carmela , Taylor, Jack C. , Tipton, Philip W. , Vandebergh, Marijne , Weıntraub, Sandra , Wong, Bonnie

Mayo Clinic

Neurology Open Access | February 18, 2026 | Volume: 2 | Issue: 1 | Pages: No page available

10.1212/wn9.0000000000000068 | PMID 41987885 Get It